Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of BMS-986442 and Nivolumab, Alone or with Chemotherapy, for Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for people with advanced solid tumors and non-small cell lung cancer. The study involves a new treatment called BMS-986442, which will be tested in combination with another medication called nivolumab. In some cases, these medications will also be combined with chemotherapy drugs such as docetaxel, paclitaxel, carboplatin, and pemetrexed disodium. The purpose of the study is to understand how safe and tolerable these combinations are for patients.

Participants in the study will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several phases, starting with a smaller group of participants to determine the best dose and then expanding to a larger group to further assess the treatment's effects. Throughout the study, researchers will monitor participants closely to observe any side effects and how well the treatment works against the cancer.

The study aims to gather important information about the new treatment's safety and how it interacts with the body. This includes looking at how the body processes the medication and any potential immune responses. The study will also evaluate the treatment's effectiveness in controlling the cancer over time. This research is crucial for developing new therapies that could improve outcomes for people with these types of cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the trial's purpose, procedures, and potential risks and benefits. You will be asked to provide informed consent, which means you agree to participate after understanding all the information provided.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm eligibility. This includes checking if you have a measurable disease and an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, which indicates your ability to perform daily activities. Your life expectancy should be at least 3 months.

  3. Step 3

    Treatment phase

    During the treatment phase, you will receive medications through an intravenous (IV) infusion. The medications include docetaxel, nivolumab, paclitaxel, bms-986442, carboplatin, and pemetrexed disodium. The specific combination and dosage will depend on the study group you are assigned to.

    The frequency and duration of administration will be explained to you by the study team. Regular monitoring will be conducted to assess the safety and effectiveness of the treatment.

  4. Step 4

    Monitoring and follow-up

    Throughout the trial, you will be monitored for any side effects or adverse events. This includes regular check-ups and tests to ensure your safety. The study aims to identify any adverse effects and determine the maximum tolerated dose of the medications.

    You will also be evaluated for the treatment's effectiveness in managing your condition. This involves measuring the response of your disease to the treatment over time.

  5. Step 5

    Completion of the trial

    At the end of the trial, a final assessment will be conducted. This includes a review of your overall health and the outcomes of the treatment.

    You will receive information about any further steps or follow-up care that may be necessary after the trial concludes.

Who can join the trial?

4 criteria

  • Participants must have a measurable disease according to specific criteria used by doctors to assess tumors.
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, which means they should be fully active or have some symptoms but can still carry out light work.
  • Participants must have a life expectancy of at least 3 months at the time of the first dose.
  • Participants can be of any gender.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • BMS-986442

    is an experimental medication being tested to see how safe it is and how well it works when used with other treatments. It is not yet approved for general use, and researchers are studying it to understand its effects on advanced solid tumors and non-small cell lung cancer. This medication is being tested to find the best dose that can be given safely to patients.

  • Nivolumab

    is a type of cancer treatment known as immunotherapy. It works by helping the body's immune system recognize and attack cancer cells. Nivolumab is already used to treat various types of cancer, and in this trial, it is being combined with other treatments to see if it can improve outcomes for patients with advanced solid tumors and non-small cell lung cancer.

  • Chemotherapy

    refers to a group of cancer-fighting drugs that work by killing rapidly dividing cells, which include cancer cells. In this trial, chemotherapy is used alongside other treatments to see if it can help improve the effectiveness of the overall treatment plan for patients with advanced solid tumors and non-small cell lung cancer.

What is already known about the treatment

BMS-986442 – BMS-986442 is an investigational medication currently being studied in clinical trials for its potential use in treating advanced solid tumors and non-small cell lung cancer. It is administered in combination with another medication called nivolumab, and sometimes with additional chemotherapy. The main goal of these studies is to determine the safety and appropriate dosage levels of BMS-986442 when used with these other treatments. This medication works by targeting specific pathways in cancer cells to help the immune system better recognize and attack these cells. BMS-986442 is still under investigation, and its effectiveness and safety are being evaluated in ongoing research.

Investigated diseases

  • Solid Tumor

    A solid tumor is an abnormal mass of tissue that usually does not contain cysts or liquid areas. These tumors can occur in various parts of the body, including organs, muscles, and bones. They are characterized by the uncontrolled growth of cells that form a lump or mass. Solid tumors can be benign, meaning they do not spread to other parts of the body, or malignant, which means they can invade nearby tissues and spread to other areas. The progression of solid tumors depends on their type, location, and whether they are benign or malignant. Malignant solid tumors may grow rapidly and invade surrounding tissues, potentially spreading to distant parts of the body.

  • Non-small Cell Lung Cancer

    Non-small cell lung cancer (NSCLC) is a type of lung cancer that includes several subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is the most common type of lung cancer, accounting for a majority of cases. NSCLC typically starts in the tissues of the lungs and can grow and spread to other parts of the body. The progression of NSCLC can vary, with some tumors growing slowly and others more rapidly. As the cancer advances, it may invade nearby tissues and organs, and potentially spread to distant sites through the bloodstream or lymphatic system. The rate of progression and spread depends on various factors, including the specific subtype and stage of the cancer.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2022-503108-26-00Protocol codeCA115-001Estimated enrolment245 patientsSponsorBristol-Myers Squibb Services Unlimited Company

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.